补肾敛肺颗粒联合噻托溴铵预防慢性阻塞性肺疾病急性加重临床观察

Clinical Observation of Prevention of Chronic Obstructive Pulmonary Disease with Acute Exacerbation by Bushenlianfei Particles Combined with Tiotropium

目的:观察补肾敛肺颗粒联合噻托溴铵防治慢性阻塞性肺疾病急性加重(AECOPD)的临床疗效。方法:选稳定期慢性阻塞性肺疾病(COPD)患者随机分治疗组75例,对照组74例。治疗组口服补肾敛肺颗粒,同时联合吸入噻托溴铵粉雾剂,连续应用12个月。对照组单纯给予吸入噻托溴铵粉雾剂。记录12个月中AECOPD次数以及住院治疗的次数;治疗前、治疗结束时测量第一秒用力呼气容积(FEV1)及FEV1占预计值,并采用圣·乔治呼吸问卷(中文版)进行生活质量评分。结果:治疗组1年中首次急性加重时间较对照组显著延长,治疗组1年中平均急性加重的次数、住院次数较对照组显著减少,治疗组治疗结束时肺功能、生活质量评估优于对照组,差异均有统计学意义(P<0.05)。结论:补肾敛肺颗粒联合噻托溴铵能显著减少COPD患者急性加重及住院次数,显著改善患者肺功能及生活质量。

Objective ： To observe clinical efficacy of prevention of chronic obstructive pulmonary disease with acute exacerba- tion （ AECOPD ） by Bushenlianfei particles combined with tiotropium. Methods ： Select stable chronic obstructive pulmonary disease （COPD） patients , and divide them randomly into treatment group of 75 cases and the control group of 74 cases. Treatment group was treated with Bushenlianfei particles combined with tiotropium for 12 months while the control group were given inhaled tiotro- pium of inhalation. Record the times of AECOPD and hospitalization in 12 months. Measure forced expiratory volume in one sec- ond （FEV~） and the predicted FEV~ % before treatment and at the end of treatment use St. George＇s Respiratory Questionnaire （Chinese version） for quality of life score. Results：The first time of acute exacerbation of the treatment group was significantly longer than that of the control group, and the number of exacerbations and hospitalization in a year of the treatment group signifi- cantly reduced on average. Compared to the control group, the lung function and quality of life assessment of treatment group were better at the end of treatment, whose differences were statistically significant （ P 〈 0. 05 ）. Conclusion ： The treatment of Bushenlian- fei particles combined with tiotropium can reduce COPD exacerbation and hospitalization, and improve lung function and quality of life of patients.